A system includes an applicator mask having an applicator surface having a three-dimensional shape corresponding to the isolated body part; and at least one membrane releasably disposed on the applicator surface and having an outer surface in facing relation with the applicator surface and inner adhesive surface opposite thereof. The membrane includes one or more benefit agents disposed in one or more treatment zones.

Certain exemplary embodiments can provide a system, machine, device, manufacture, circuit, composition of matter, and/or user interface adapted for and/or resulting from, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise and/or relate to, controlling delivery of a transdermally-delivered medication, certain embodiments including a flux controller.

Various embodiments of patient-mittens are disclosed and described. Such embodiments may include a hand-covering portion attached to a hollow elongate-sleeve portion. The hand-covering portion may cover the hand and fingers, preventing the patient from scratching themselves. The elongate-sleeve portion may cover a majority of an arm. Opposite from the hand-cover portion, there may be an arm-grabber attached at an end of the elongate-sleeve. This arm-grabber may squeeze the upper arm, above the elbow, to help keep the patient-mitten from coming off. Some embodiments, may include an access-slit on the elongate-sleeve for placing IVs and the like in a patient wearing the patient-mitten. The patient-mitten may help to minimize IVs and vital sign sensors from becoming dissociated from the patient. Some embodiments may be UV permeable to encourage vitamin D production in the patient. Some embodiments may provide a conducive environment for treating skin conditions on the arm, hand, or fingers.

A hydrogen-enhanced drug delivery system for hydrogen-assisted transdermal delivery of a therapeutic agent is provided. The system includes a hydrogen-generating compartment comprising at least one dry chemical. Addition of an activator, such as a liquid composition, from within or outside of the system, causes the dry chemical(s) to generate molecular hydrogen (H.sub.2) within the system. The molecular hydrogen passes through a skin-contacting surface of the system, which is permeable to hydrogen and not permeable to the dry chemical(s) and the liquid composition, and enhances the release of the therapeutic agent from the system as H.sub.2 is delivered to the subject's body. The H.sub.2 can also enhance the therapeutic effect of the therapeutic agent.

A carbon dioxide slow-release pack for skin according to the present invention is a carbon dioxide slow-release pack which has a bag shape for slowly releasing carbon dioxide enclosed therein, thereby bringing the carbon dioxide into contact with the skin, and is formed into a bag shape by at least a resin sheet (A), and the resin sheet (A) satisfies at least the following requirements (A-1) and (A-2): (A-1) A carbon dioxide permeability measured under the conditions of 23 C. and a relative humidity of 0% according to JIS K7126-1 is 20 L/(m.sup.2.Math.day.Math.atm) or more, (A-2) An Oken-type air permeability measured at 23 C. according to JIS P8117: 2009 is less than 5 m/(Pa.Math.s).

A radiation dermatitis prevention apparatus includes: a pack (10), including: a pocket (12) including a face panel (16) and a back panel (18), wherein the panels (16, 18) are secured to each other along their respective peripheries in such a way as to define an opening (20), wherein the face panel (16) is constructed from a material suitable for contact with a patients skin and which readily permits fluid to flow through its thickness; and an insert (14) sized to fit in the opening (20) and made of a material which is suitable for holding and releasing a radiation cream in viscous fluid form.

A system and method of electrotherapy for enhanced drug delivery, comprising an electrode patch and an electrotherapy apparatus providing electrical current onto the electrode patch. The electrode patch contains one or more active drug ingredients in a layer of conductive gel, and the electrotherapy apparatus provides electrical current onto the electrode patch for the enhanced drug delivery of active drug ingredients. The conductive gel is in contact with a human or animal body, and the electrode patch also includes a layer of conductive sheet, a supporting layer, and conductive connectors. The conductive gel has the viscosity allowing it to adhere to skin on a human or animal body. The active drug ingredients that can be delivered through the conductive gel include: lidocaine, capsaicin, menthol, camphor, methyl salicylate, trolamine salicylate, Arnica montana, Calendula officinalis, Hypericum perforatum, Symphytum officinale, cannabidiol (CBD) or any combination of these substances. The mass fraction of the active drug ingredients can vary from 0.001% to 30%. The electrotherapy device can be reused.

A composition for healing or improving skin includes a fabric or material impregnated with an oxygen generating material. The fabric may include a first side in contact with the skin for providing oxygen to the skin and a second side between the oxygen generating material and the air surrounding the skin to form a barrier for retaining heat and inhibiting evaporation.

A delivery device includes a collar device for wearing on an animal, a dosing probe disposed on the collar device for delivering a substance therefrom, an actuator configured to deliver the substance from the dosing probe through an opening formed in the dosing probe, a controller in communication with the actuator and configured to control delivery of the substance from the dosing probe, and a sensor in communication with the controller and configured to sense that the collar device is touching fur or skin of the animal and the dosing probe is directed towards fur or skin of the animal.

Dry eye treatment apparatus and methods are described herein which generally comprise a patch or strip affixed to the skin of the upper and/or lower eyelids to deliver heat or other forms of energy, pressure, drugs, moisture, etc. (alone or in combination) to the one or more meibomian glands contained within the underlying skin. The treatment strip or strips include one or more strips configured to adhere to an underlying region of skin in proximity to one or both eyes of a subject such that the one or more strips allow for the subject to blink naturally without restriction from the one or more patches. Moreover, the one or more strips may be configured to emit energy to the underlying region of skin and where the one or more strips are shaped to follow a location of one or more meibomiam glands contained within the underlying region of skin.